DUBLIN–(BUSINESS WIRE)–The “Angiotensin Converting Enzyme (ACE) Inhibitor – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
“Angiotensin Converting Enzyme (ACE) Inhibitor – Pipeline Insight, 2022” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Converting Enzyme (ACE) Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Angiotensin Converting Enzyme (ACE) Inhibitor
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Angiotensin Converting Enzyme (ACE) Inhibitor
The report assesses the active Angiotensin Converting Enzyme (ACE) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the Report
- Provides a snapshot of the therapeutics pipeline activity for Angiotensin Converting Enzyme (ACE) Inhibitor
- Features the Angiotensin Converting Enzyme (ACE) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
- Offers detailed therapeutic product profiles of Angiotensin Converting Enzyme (ACE) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Angiotensin Converting Enzyme (ACE) Inhibitor
Key Topics Covered:
1. Report Introduction
2. Angiotensin Converting Enzyme (ACE) Inhibitor – Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Angiotensin Converting Enzyme (ACE) Inhibitor
4. Comparative Analysis
5. Angiotensin Converting Enzyme (ACE) Inhibitor Pipeline Products in Clinical Stages
- Product Description
- Research and Development
- Product Development Activities
6. Angiotensin Converting Enzyme (ACE) Inhibitor Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- Product Description
- Research and Development
- Product Development Activities
- Reason for dormancy/discontinuation
Companies Mentioned
- Gene PreDiT
- Marina Biotech
- Proveca
- Daewon Pharmaceutical
- Ethicare GmbH
- Ferrer
- Jeil Pharmaceutical
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/p440z7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900